Drugs / BG-C9074
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06233942 | Apr 2024 → Sep 2027 expected | neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07811271 | Oct 2026 → Nov 2029 expected | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | BeOne Medicines | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | BeOne Medicines | Results BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 beonemedicines.com ↗
Anti-tumor activity demonstrated in OC regardless of B7-H4 expression level. |
| 2025-06-26 | BeOne Medicines | Results BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day beonemedicines.com ↗
Promising new data for the B7-H4 ADC (BG-C9074) point to a potential first-in-class therapeutic option for patients with B7-H4 expressing tumors, including those without selection criteria. |
| 2025-06-02 | BeOne Medicines | Results BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 beonemedicines.com ↗
These early results highlight the strong potential of our B7-H4-targeting ADC and CDK2 inhibitor to address critical gaps in breast cancer treatment. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | BeOne Medicines | BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 beonemedicines.com ↗ |
| 2025-06-26 | BeOne Medicines | BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day beonemedicines.com ↗ |
| 2025-06-02 | BeOne Medicines | BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 beonemedicines.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-C9074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07811271 ↗ |
| Action | Deplete | “After it attaches to B7-H4, BG-C9074 enters the cancer cell where the drug causes DNA damage and cell death.” NCT07811271 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT06233942 ↗ |